Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Non-cash Items (2018 - 2024)

Historic Non-cash Items for Zevra Therapeutics (ZVRA) over the last 9 years, with Q4 2024 value amounting to $2.4 million.

  • Zevra Therapeutics' Non-cash Items fell 7836.32% to $2.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.4 million, marking a year-over-year decrease of 7836.32%. This contributed to the annual value of $2.4 million for FY2024, which is 7836.32% down from last year.
  • Zevra Therapeutics' Non-cash Items amounted to $2.4 million in Q4 2024, which was down 7836.32% from $11.1 million recorded in Q4 2023.
  • Zevra Therapeutics' 5-year Non-cash Items high stood at $11.8 million for Q4 2022, and its period low was $254207.0 during Q4 2021.
  • Over the past 5 years, Zevra Therapeutics' median Non-cash Items value was $2.4 million (recorded in 2024), while the average stood at $5.2 million.
  • In the last 5 years, Zevra Therapeutics' Non-cash Items skyrocketed by 454936.06% in 2022 and then tumbled by 7836.32% in 2024.
  • Zevra Therapeutics' Non-cash Items (Quarter) stood at $543021.0 in 2020, then tumbled by 53.19% to $254207.0 in 2021, then skyrocketed by 4549.36% to $11.8 million in 2022, then dropped by 6.18% to $11.1 million in 2023, then crashed by 78.36% to $2.4 million in 2024.
  • Its Non-cash Items stands at $2.4 million for Q4 2024, versus $11.1 million for Q4 2023 and $11.8 million for Q4 2022.